FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to 4-[3-(4-cyclopropanecarbonyl-piperazin-1-carbonyl)-4-fluor-benzyl]-2H-phthalazin-1-one in the form of a crystalline form L having characteristic peaks on an X-ray powder diffraction pattern presented in the patent claim, to methods for preparing the form L, pharmaceutical formulation containing the form L, and versions of using the form L and formulations containing the form L.
EFFECT: preparing the new crystalline form of the above compound which possesses poly-(ADP)polymerase (PARP) inhibitory activity The form L contains no solvent impurities that enables more accurate dosage of the active compound when treating the patient.
17 cl, 4 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYMORPHOUS FORM OF 4-[3-(4-CYCLOPROPANE CARBONYL PIPERAZINE-1-CARBONYL)-4-FLUOROBENZENE)-2H-PHTHALAZIN-1-ONE | 2007 |
|
RU2465270C2 |
| DNA REPAIR INHIBITORS FOR CANCER THERAPY | 2004 |
|
RU2413515C2 |
| INHIBITORS OF DNA DAMAGE REPAIR FOR CANCER TREATMENT | 2017 |
|
RU2755865C2 |
| METHODS BASED ON DETECTING RAD51 FOCI IN TUMOUR CELLS | 2018 |
|
RU2825699C2 |
| METHODS OF APPLYING SNS-595 FOR TREATMENT OF SUBJECTS WITH ONCOLOGIC DISEASES WITH REDUCED BRCA2 ACTIVITY | 2010 |
|
RU2558835C2 |
| METHOD OF TREATING BREAST CANCER WITH COMPOUND OF 4-IODINE-3-NITROBENZAMINE IN COMBINATION WITH ANTICANCER AGENTS | 2008 |
|
RU2480211C2 |
| TRICYCLIC PARP INHIBITORS | 2004 |
|
RU2404183C2 |
| PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3-YL]PHENYL}-2H-INDAZOLE-7-CARBOXAMIDE | 2009 |
|
RU2495035C2 |
| HETEROCYCLIC IMIDAZOLE COMPOUNDS, METHOD FOR THE PRODUCTION AND USE THEREOF | 2016 |
|
RU2686314C1 |
| COMBINED THERAPY WITH TETRACYCLIC QUINOLONE ANALOGUES FOR CANCER TREATMENT | 2016 |
|
RU2752506C2 |
